Yayın: Implications of NLRP3 suppression using glibenclamide and miR-223 against colorectal cancer
| dc.contributor.author | Hamza, Shaimaa | |
| dc.contributor.author | Garanina, Ekaterina E. | |
| dc.contributor.author | Shkair, Layaly | |
| dc.contributor.author | Alsaadi, Mohammad | |
| dc.contributor.author | Khaiboullina, Svetlana F. | |
| dc.contributor.author | Tezcan, Gülçin | |
| dc.contributor.buuauthor | TEZCAN, GÜLÇİN | |
| dc.contributor.department | Diş Hekimliği Fakültesi | |
| dc.contributor.department | Temel Bilimler Bölümü | |
| dc.contributor.researcherid | JJL-1176-2023 | |
| dc.date.accessioned | 2025-01-28T07:38:51Z | |
| dc.date.available | 2025-01-28T07:38:51Z | |
| dc.date.issued | 2024-03-01 | |
| dc.description.abstract | The NLR family pyrin domain containing 3 (NLRP3) promotes the growth of colorectal cancer (CRC). However, the therapeutic effect of NLRP3 inhibition on CRC cell progression is controversial. This study comparatively investigated the therapeutic effect of a pharmacological NLRP3 inhibitor, glibenclamide (gli), and the post-translational suppression of NLRP3 by miR-223 on CRC cell progression in HCT-116 and HCT-15 cells. LPS and ATP were used to activate Gli-treated and LSB-hsa-miR-223-3p (WTmiR-223)-expressing HCT-116 cells. NLRP3.AB.pCCL.sin.cPPT.U6.miR-223-Decoy.hPGK.GFP.WPRE plasmid (DmiR-223) was the negative control for miR-223 expression. NLRP3, gasdermin D, and BAX expressions were analyzed using western blotting. Real-time PCR detected the RNA expression of autophagy-related genes ATG5, BECN1, and miR-223 in non-transfected cells. ELISA analyzed IL-1 beta and IL-18 in the medium. MTS-1, annexin V, wound-healing, and sphere-invasion assays were used to assess cell viability and progression. A multiplex cytokine assay detected proinflammatory cytokine secretion. LPS-ATP-activated NLRP3 produced gasdermin D cleavage, released IL-1b and IL-18, and activated cell migration and sphere invasion. In contrast, reduced cell growth, miR-223 expression, IFN-gamma, CXCL10, and LIF secretion were found in cells after inflammasome activation. Both gli and WTmiR-223 induced autophagy genes ATG5 and BECN1 and reduced the NLRP3 activation and its downstream proteins. However, while gli had a limited effect on the production of IFN-gamma, CXCL10, and LIF, WTmiR-223 increased the release of those cytokines. In addition, gli did not suppress cell growth, while WTmiR-223 promoted apoptosis. Notably, neither gli nor WTmiR-223 effectively prevented sphere invasion. These data suggest that, while WTmiR-223 could have a better anticancer effect in CRC compared to gli, the sole usage of miR-223-mediated NLRP3 suppression may not be sufficient to prevent CRC metastasis. | |
| dc.description.sponsorship | Kazan Federal University Strategic Academic Leadership Program | |
| dc.identifier.doi | 10.3390/ph17030299 | |
| dc.identifier.issue | 3 | |
| dc.identifier.scopus | 2-s2.0-85189030707 | |
| dc.identifier.uri | https://doi.org/10.3390/ph17030299 | |
| dc.identifier.uri | https://www.mdpi.com/1424-8247/17/3/299 | |
| dc.identifier.uri | https://hdl.handle.net/11452/49864 | |
| dc.identifier.volume | 17 | |
| dc.identifier.wos | 01193006600001 | |
| dc.indexed.wos | WOS.SCI | |
| dc.language.iso | en | |
| dc.publisher | Mdpi | |
| dc.relation.journal | Pharmaceuticals | |
| dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | |
| dc.rights | info:eu-repo/semantics/openAccess | |
| dc.subject | Inflammasome activation | |
| dc.subject | Growth-factor | |
| dc.subject | Inhibition | |
| dc.subject | Receptor | |
| dc.subject | Mechanism | |
| dc.subject | Autophagy | |
| dc.subject | Cells | |
| dc.subject | Proliferation | |
| dc.subject | Sulfonylureas | |
| dc.subject | Microrna-223 | |
| dc.subject | Nlrp3 | |
| dc.subject | Inflammasome | |
| dc.subject | Glibenclamide | |
| dc.subject | Microrna-223 | |
| dc.subject | Colorectal cancer | |
| dc.subject | Metastasis | |
| dc.subject | Pharmacology & pharmacy | |
| dc.title | Implications of NLRP3 suppression using glibenclamide and miR-223 against colorectal cancer | |
| dc.type | Article | |
| dspace.entity.type | Publication | |
| local.contributor.department | Diş Hekimliği Fakültesi/Temel Bilimler Bölümü | |
| local.indexed.at | WOS | |
| local.indexed.at | Scopus | |
| relation.isAuthorOfPublication | e171a866-0a2e-4df4-9f4b-d9058971c979 | |
| relation.isAuthorOfPublication.latestForDiscovery | e171a866-0a2e-4df4-9f4b-d9058971c979 |
Dosyalar
Orijinal seri
1 - 1 / 1
